Completed PHASE2 INTERVENTIONAL 1-arm NCT02758548

Determination of Accuracy in Measurement of Total Immunoglobulin E Using a Test Device in Atopic Subjects

A Multicenter Clinical Evaluation Study to Determine the External Site Accuracy of Total Immunoglobulin E Measurement Using a Novel Point of Care Test Device Compared to a Reference Method in Atopic Subjects

Sponsor: Novartis Pharmaceuticals

Conditions Atopic Asthma

Interventions Blood sample POCT device

Updated 6 times since 2017 Last updated: Nov 13, 2016 Started: Mar 31, 2016 Primary completion: May 31, 2016 Completion: May 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Atopic Asthma and is currently completed. Novartis Pharmaceuticals leads this study, which shows 6 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Almelo, Netherlands , Bradford, United Kingdom , Chertsey, United Kingdom , Hamburg, Germany , Harderwijk, Netherlands , Lübeck, Germany , Manchester, United Kingdom , Padua, Italy , Pisa, Italy , Roma, Italy and 2 more locations